RDHL News Alert Redhill Biopharma Ltd (RDHL) 12.22 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Redhill Biopharma Ltd (RDHL) 12.22 $RDHL

RedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn's Program
GlobeNewswire - Thu Dec 18, 5:05AM CST
-- The acquired diagnostic technology is intended for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) bacterium; Increasing evidence supports the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients
RDHL: 12.22 (-0.13), DGX: 67.94 (-0.16)

RedHill commences new Phase 3 Bekinda study in U.S.
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:03AM CST

RDHL: 12.22 (-0.13)

RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA(TM)) for Gastroenteritis and Gastritis
GlobeNewswire - Wed Dec 17, 5:05AM CST
-- The randomized, double-blind, placebo-controlled Phase III study with RHB-102 for acute gastroenteritis and gastritis (the GUARD study) is underway in the U.S., with a planned enrollment of 320 patients
RDHL: 12.22 (-0.13)

Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 15.35 (+0.30), BIIB: 340.89 (+5.13), IMMU: 4.41 (+0.13), RDHL: 12.22 (-0.13), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), ARGS: 9.65 (+0.34), NVO: 43.80 (+1.08), IDRA: 3.89 (+0.02), ANTH: 1.48 (unch), MRK: 57.46 (+0.25), CBMG: 12.98 (+0.19), CELGZ: 3.34 (-0.01)

RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST

INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)

RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application for Oncology Support
GlobeNewswire - Tue Dec 09, 5:33AM CST
-- RHB-102, newly branded as BEKINDA, is a proprietary once-daily oral pill formulation of the antiemetic drug ondansetron
RDHL: 12.22 (-0.13)

RedHill Biopharma to Sponsor and Exhibit Its Ongoing Phase III Crohn's Program at the Israeli IBD Society Meeting
GlobeNewswire - Tue Dec 02, 6:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that it will provide Silver Sponsorship for the Israeli IBD (Inflammatory Bowel Disease) Society meeting to be held December 9, 2014 at the Dan Hotel in Tel-Aviv, Israel. The Israeli IBD Society meeting aims to promote collaborations and research initiatives in the field of diagnosis and treatment of inflammatory bowel diseases.
RDHL: 12.22 (-0.13)

German regulator starts review of Rizaport MAA
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:43AM CST

RDHL: 12.22 (-0.13)

IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:03AM CST
-- The German Federal Institute for Drugs and Medical Devices ("BfArM" has validated the European Marketing Authorization Application submitted for RIZAPORT(TM) and initiated its formal review of the application on November 25, 2014
RDHL: 12.22 (-0.13), IGX.VN: 0.570 (unch)

RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:00AM CST
-- The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT (RHB-103) and initiated its formal review of the application on November 25, 2014
RDHL: 12.22 (-0.13), IGX.VN: 0.570 (unch)

Redhill Biopharma's (RDHL) CEO Dror Ben Asher on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:01PM CST

RDHL: 12.22 (-0.13)

FDA tags RedHill's RHB-105 a QIDP
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:02AM CST

RDHL: 12.22 (-0.13)

Redhill beats by $0.44
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:11AM CST

RDHL: 12.22 (-0.13)

FDA Grants QIDP Fast-Track Designation to RedHill Biopharma's Phase III H. pylori Drug RHB-105
GlobeNewswire - Mon Nov 10, 6:28AM CST
-- Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to existing exclusivity, Fast-Track status (an expedited development pathway) and Priority Review status (shortened review time for marketing applications)
RDHL: 12.22 (-0.13)

RedHill Biopharma Reports Results for the Third Quarter of 2014
GlobeNewswire - Mon Nov 10, 5:30AM CST
-- A strong cash position of approximately $29 million at the end of the third quarter of 2014, enabling the Company to continue to execute its R&D programs including the three ongoing Phase III studies in gastrointestinal indications: RHB-104 for Crohn's disease, RHB-105 for H. pylori infection and RHB-102 for acute gastroenteritis and gastritis
RDHL: 12.22 (-0.13)

RedHill Bio reports November 10
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 9:39AM CDT

RDHL: 12.22 (-0.13)

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014
GlobeNewswire - Tue Oct 28, 6:15AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that it will report financial results for the third quarter of 2014 on Monday, November 10, 2014.
RDHL: 12.22 (-0.13)

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference
GlobeNewswire - Wed Oct 22, 8:44AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill" , an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will be presenting at the 20 Annual BIO-Europe International Partnering Conference, on Tuesday, November 4, 2014, at 10:00 a.m., in the Transparenz room of the Portalhaus Messe Frankfurt, in Frankfurt, Germany.
RDHL: 12.22 (-0.13)

This Small Cap Is Poised To Tap Multi-Billion Dollar Migraine Treatment Market
Tedra DeSue - at Seeking Alpha - Thu Oct 16, 8:14AM CDT

RDHL: 12.22 (-0.13)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 69

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading

Top 5 Most Recently Viewed Articles

An In-Depth Analysis of Qorvo's Current Short Interest Trends

Updated Category News Views 215

Understanding Qorvo's Short Interest Movement Qorvo Inc. (NASDAQ: QRVO) has been experiencing notable changes in its short interest, with a recent report indicating a decrease of 16.17%. This drop reflects a total of 5.20 million shares sold short, equating to about 7.67% of the total shares available for trading. Traders should note that, with the current trading volume,...

Continue Reading
Sev1Tech Secures $188M Contract with U.S. Space Force

Updated Category News Views 167

Sev1Tech Secures a Major Contract with the U.S. Space Force Sev1Tech has recently made headlines by being awarded a substantial contract valued at $188 million from the U.S. Space Force (USSF), specifically under the Space Systems Command (SSC). This contract involves expanding the support for an innovative and powerful network known as meshONE-T. This network is...

Continue Reading
Exploring Rigetti Computing's Growth and ETF Impact

Updated Category News Views 339

Understanding the Surge of Rigetti Computing Rigetti Computing Inc. (NASDAQ: RGTI) has seen an extraordinary performance recently, with its shares rising a staggering 100% year-to-date, and almost 3,900% over the past year. This impressive increase has attracted considerable investor interest, particularly from those focused on opportunities in the rapidly evolving...

Continue Reading
Kratos Defense Stock Climbs High: What Investors Should Know

Updated Category News Views 198

Kratos Defense Stock Reaches New Heights Kratos Defense (NASDAQ: KTOS) has recently achieved a remarkable milestone by hitting a 52-week high of $30.42. This achievement comes amid a strong defense market, marking a significant increase in the company's stock value with a one-year growth of 55.96%. Investors demonstrate growing confidence in Kratos, renowned for its...

Continue Reading
Precision Linear Actuators for Optical and Automation Needs

Updated Category News Views 143

High-Precision Micro-Positioning Solutions Available For those seeking reliability and accuracy in optical alignment, precision automation, and research applications, the latest offerings from PI deliver exceptional results. Introducing the L-220 Series Linear Actuators PI’s L-220 series linear actuators are designed for applications demanding sub-micrometer precision....

Continue Reading